SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
Company to open new headquarters in 2024
48-week data from MOMENTUM phase III clinical trial show momelotinib maintained total symptom response
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan
Julie Brown is currently Chief Operating and Financial Officer, Burberry Group.
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
Completion of the demerger of Haleon and share consolidation of GSK
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Subscribe To Our Newsletter & Stay Updated
